CymaBay gains on seladelpar data

CymaBay Therapeutics Inc. (NASDAQ:CBAY) was up $1.37 (11%) to $13.44 on Wednesday after reporting additional interim data from a Phase II trial of seladelpar (MBX-8025) to treat primary biliary cholangitis in patients who had an inadequate response or intolerance to ursodeoxycholic acid. The company also reiterated its plans to start Phase III testing next half for the PPAR delta agonist to treat PBC.

On the open-label trial's primary efficacy endpoint, once-daily doses of oral seladelpar reduced mean alkaline phosphatase levels from baseline to week 12 by 21% at the 2 mg dose, 33% at the 5 mg dose and 45% at the 10 mg dose...